This legislative season has seen key pharmacy benefit manager reforms but slow movement on other issues, such as copay accumulators and utilization management. The ACR is also monitoring emerging topics, such as biomarker testing and post-public health emergency telehealth reforms.
Search results for: drug pricing
Mark Cuban: Mixing Up the Pharmaceutical Landscape
The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…
Clinical Academic Rheumatology Generates Profits for Health Systems
Rheumatologists should be better compensated, in part, due to the revenue they bring to the hospital system from their procedures, argue D’Anna et al., who found that clinical academic rheumatologists bring significant downstream revenue to the healthcare system.
ACR President, Affiliate Society Council Hold First Town Hall
In late August, leaders of state and local rheumatology societies from across the nation connected with each other and with ACR president Ken Saag, MD, in a roundtable-style meeting. State and local rheumatology leaders shared local updates, successes and challenges and discussed ACR initiatives.
New Healthcare Price Transparency Requirements Are Complicated & Vary by State
Healthcare law is ever changing, particularly with regard to price transparency. Key healthcare leaders and stakeholders have long argued for more stringent price transparency regulations in an effort to increase patient awareness regarding the cost of a hospital item or service prior to receiving the service. Such information is anticipated to enable patients to take…
‘Battle for Health Justice’: Dr. Alakija Addresses Global Rheumatology Inequities
On Nov. 3, the inaugural, virtual Global Rheumatology Summit brought together specialists from all over the world to share critical expertise on global health issues related to rheumatology.
Insight into the Biosimilar Prescribing Habits of Rheumatologists
The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.
Rheumatology Care: Access & Affordability
Presenters at the Access in Rheumatology meeting held in advance of the ACR’s State-of-the-Art Clinical Symposium took a deep dive into the access challenges faced by rheumatology patients and discussed possible solutions. Treatment At least until 2026, prescription drug spending will exceed the U.S. gross domestic product (GDP) and health spending, said rheumatologist Colin C….
2020 State Legislative Roundup: The Year That Could Have Been & the Year That Was
The COVID-19 pandemic and response disrupted state legislative sessions and agendas in 2020, leaving many ACR priorities unfulfilled and highlighting the urgent need for vocal rheumatology leaders in Washington, D.C., and state capitols.
Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology
As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 21
- Next Page »